A pan-European registration system for volunteer participation is within sight

K. Berelowitz · J. Taubel

Received: 13 June 2012 / Accepted: 9 July 2012 / Published online: 29 July 2012
© Springer-Verlag 2012

13 June 2012

Dear Editor,

Boyce et al. [1] reflect on the use of one of several trial participant registers but they fail to give a balanced appraisal of the full spectrum of systems available. The authors claim that “We have no evidence that healthy subjects travel from other EU countries just to volunteer for a clinical trial in our unit.” This is incongruous with our experience; they do. Possibly a small problem in Leeds or Erfurt, it is a considerable problem in locations such as Basel, Cologne, or London where borders are nearby or transportation is good. The authors appear to oppose a wider EU initiative. To publish in the *European Journal of Clinical Pharmacology* seems an odd choice when all they want is to promote an insular mentality in which all is supposedly well for the UK.

The Overvolunteering Prevention System (TOPS) is claimed to have achieved a success in preventing volunteers from overvolunteering, yet the authors do not provide evidence that this has in fact been achieved. They show that their detection rate has declined over the years yet do not discuss other possible explanations for this phenomenon; amongst other reasons, such as the general decline in the number of trials in the UK, one very obvious explanation would be that volunteers have found ways to circumvent their detection. TOPS is an imperfect system: it allows multiple registrations by, for example, the use of a national insurance number in one unit and a passport in another. Data presented by the authors show that TOPS is underutilised: its UK competitor, the National Volunteer Register (NVR) holds just under 130,000 records from one single site, so it is of an approximately equal size to TOPS. Assuming a 5–10 % market share of that particular unit, TOPS should hold records for the remaining 90–95 % of volunteers, i.e. well over one million records. Even assuming some

overlap between the two systems, it shows that TOPS is not as widely used as the authors wish to claim. The reason may well be that TOPS is run by a contact research organisation (CRO) and that there may be some degree of apprehension by other users to submit data to one of their competitors.

There are initiatives under way to create a European search system using a different approach than that of TOPS, Volunteer Inclusion Period (VIP)-Check, NVR and Volontaires Recherches Biomedicales (VRB). The latter systems are databases, whilst the former is a search engine only for accessing data held by clinical trial sites where it remains under the control of the local data controllers. It is collectively controlled by its users, and searches are based on robust personal identifiers yet provide better data protection to users submitting their data and the individuals whose data is accessed. Trials are under way in Germany and the UK and are scheduled for Belgium and Holland later this year. The system is low cost, flexible, not labour intensive to users, resilient to unauthorized access by hackers and, above all, international.

No single database is likely to be established across Europe. Contrary to the authors’ assertion, France has the most sophisticated system in Europe for preventing volunteers from overvolunteering, but it can only do so in France. As with any national system, it is incapable of tracking volunteers crossing borders. VIP-Check or TOPS effectively are privately owned local service providers and can only ever be an addition but not an alternative to a search-engine-based system, which will be a major improvement over the current state of play.

With kind regards,
Dr. Jörg Täubel

References

1. Boyce M, Walther M, Nentwich H, Kirk J, Smith S, Warrington S (2012) TOPS: an internet-based system to prevent healthy subjects from over-volunteering for clinical trials. *Eur J Clin Pharmacol* 68 (7):1019–1024

K. Berelowitz · J. Taubel (✉)
Richmond Pharmacology Ltd., St George’s University of London,
London, UK
e-mail: j.taubel@richmondpharmacology.com